itroglycerin as a sensitizer in the treatment of non small cell lung cancer: ;a phase II trial. - Nitroglycerine phase II

MAASTRO clinic0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Non-small cell lung cancer stage IB-IV amenable for radiotherapy with curative intent.
•- (Stage IV patients with oligometastatic (1-4 metastases) NSCLC are regularly treated radically in the IKL region)
•- Patients not included in the PET-boost trial.
•- WHO performance status 0-2
•- Willing and able to comply with the study prescriptions
•- 18 years or older
•- Ability to give and having given written informed consent before patient registration
•- No recent (less than 3 months) severe cardiac disease (NYHA class higher than 1) (congestive heart failure, infarction)
•- No radiotherapy in 4 weeks prior to this study
•- No treatment with investigational drugs in 4 weeks prior to or during this study.
•- No known allergy to nitroglycerin or nitroglycerin patch.
•- No known allergy to iodine based contrast agents
•- No use of vaso-dilators (calcium channel blockers, nitrates or 5-fosfodiesterase inhibitors)
•- No symptomatic hypotension
•- No other active malignancy
•- No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy) in previous 4 weeks
•- Adequate renal function: calculated creatinine clearance at least 60 ml/min

发起方